Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail

doi:10.5306/wjco.v14.i8.285

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4113)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

WORD

HTML

2527

Figures (1-3)

305

Tables (1-2)

283

Sum=3211

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

134

Download

357

Sum=491

Publishing Process of This Article

Item

Count

Browse

Download

154

Sum=242

Aug 24, 2023 (publication date) through May 14, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Oncol. Aug 24, 2023; 14(8): 285-296
Published online Aug 24, 2023. doi: 10.5306/wjco.v14.i8.285

Table 2 Phosphoinositide 3-kinase-protein kinase-mammalian target of rapamycin-pathway inhibitors

Agent	Combination	Phase	NCT number¹
PI3K inhibitors (p110α) isoform
Alpelisib (BYL719)	Gemcitabine and abraxane	I	NCT02155088
Buparlisib (BKM120)	mFOLFOX6; trametinib (MEKi)	I; I	NCT01571024; NCT01155453
Pan-PI3K inhibitors
Copanlisib(BAY 80–6946)	N/A	I	NCT00962611
PI3K and mTOR inhibitors
Voxtalisib (SAR245409, XL765)	N/A	I	NCT00485719
Dactolisib(NVP-BEZ235)	MEK162 (MEKi)	I	NCT01337765
Gedatolisib (PF-05212384, PKI-587)	Palbociclib (CDKi)	I	NCT03065062
Pan-Akt inhibitors
MK2206	Monotherapy; dinaciclib (CDKi); selumitinib (MEKi) vs mFOLFOX6	I; I; II	NCT00848718; NCT01783171; NCT01658943
Afuresertib (GSK2110183)	Trametinib (MEKi); N/A	I; II	NCT01476137; NCT01531894
Uprosertib (GSK2141795)	Trametinib (MEKi)	I	NCT01138085
Oleandrin (PBI-05204)	N/A	II	NCT02329717
Perifosine	N/A	II; II	NCT00053924; NCT00059982
RX-0201	Gemcitabine	II	NCT01028495
Rapalogs (mTORC1 inhibitors)
Sirolimus (rapamycin)	Sunitinib (RTKi); N/A; metformin; vismodegib (SMOi)	I; II; I/II; I	NCT00583063; NCT00499486; NCT02048384; NCT01537107
Temsirolimus (CCI-779, Torisel)	Lenalidomide; gemcitabine; nivolumab (PD-1i)	I; I; I/II	NCT01183663; NCT00593008; NCT02423954
Everolimus (RAD001)	Sorafenib (RTKi); trametinib (MEKi); gemcitabine; cetuximab (EGFRi) and capecitabine; N/A	I; I; I/II; I/II; II	NCT00981162; NCT00955773; NCT00560963; NCT01077986; NCT00409292
Ridafirolimus	Bevacizumab (VEGFRi)	I	NCT00781846
mTORC1/2 inhibitors
Vistusertib (AZD2014)	N/A; selumitinib (MEKi); olaparib (PARPi)	I; II; II	NCT01026402; NCT02583542; NCT02576444

¹clinicaltrials.gov

PI3K: Phosphoinositide 3-kinase; NCT: National clinical trial; MEKi: Mitogen-activated protein kinase/ extracellular regulated protein kinases inhibitor; CDKi: Cyclin-dependent kinase inhibitor; RTKi: Receptor tyrosine kinase inhibitor; SMOi: Smoothened inhibitor; PD-1i: Programmed cell death receptor-1 inhibitor; EGFRi: Epidermal growth factor receptor inhibitor; VEGFRi: Vascular endothelial growth factor receptor inhibitor; mTOR: mammalian target of rapamycin; PARPi: Poly (ADP-ribose) polymerase inhibitor; N/A: Not applicable.

Citation: Elhariri A, Alhaj A, Ahn D, Sonbol MB, Bekaii-Saab T, Wu C, Rutenberg MS, Stauffer J, Starr J, Majeed U, Jones J, Borad M, Babiker H. Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail. World J Clin Oncol 2023; 14(8): 285-296
URL: https://www.wjgnet.com/2218-4333/full/v14/i8/285.htm
DOI: https://dx.doi.org/10.5306/wjco.v14.i8.285